{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:09:58Z","timestamp":1792091398295,"version":"4.4.0"},"reference-count":53,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cancer research UK, UK RadNet Manchester","award":["C1994\/A28701"],"award-info":[{"award-number":["C1994\/A28701"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: ACEIs protect against radiation pneumonitis by reducing angiotensin II production, oxidative stress, and inflammation. This study highlights the significance of concurrent angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) use in radiotherapy by evaluating its impact on radiotherapy-related side effects and survival outcomes, addressing the gap in existing research and providing insights to guide clinical practice in oncology. Methods: The literature was retrieved from the MEDLINE, EMBASE, Web of Science, and Scopus databases from January 2000 to October 2024. Studies on adults (\u226518 years) with histologically confirmed cancer, receiving ACEIs or ARBs during radiotherapy, were included. Radiotherapy-related side effects and clinical outcomes were analysed using odds ratios (ORs) and 95% confidence intervals (95%CIs), comparing ACEI\/ARB users to non-users. Differences in the median survival time, recurrence, and death rates were also calculated. Results: Sixteen studies (14 cohort studies and two randomised trials) were included. ACEI users exhibited a 50% reduction in the risk of \u2265grade 2 radiation pneumonitis (OR: 0.50, 95%CI: 0.32\u20130.77) in lung cancer and significant reductions in the odds of proctitis (80%, OR: 0.20, 95%CI: 0.12\u20130.33), haematuria (75%, OR: 0.25, 95%CI: 0.16\u20130.41), and rectal bleeding (61%, OR: 0.39, 95%CI: 0.30\u20130.51) in prostate cancer. ACEI\/ARB users showed reduced symptomatic radiation necrosis in brain metastases and better 6-month functional independence in supratentorial glioblastoma. Among six studies reporting survival, ACEI\/ARB users had longer median survival in early-stage non-small-cell lung cancer and glioblastoma but shorter survival in small cell lung cancer and brain metastases. ARB users had inconsistent survival rates for lung cancer. The varying survival outcomes suggest that ACEIs\/ARBs have different effects depending on the cancer type and stage, potentially influenced by cancer-specific factors, treatment protocols, or disease progression. Conclusions: ACEI use is associated with a reduction in radiation pneumonitis, but evidence for other radiotherapy-related toxicity and survival outcomes remains inconsistent across cancer types and severities. Further research should carefully control for confounders.<\/jats:p>","DOI":"10.3390\/ph18010105","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T04:55:19Z","timestamp":1737003319000},"page":"105","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Effect of the Concurrent Use of Angiotensin-Converting Enzyme Inhibitors or Receptor Blockers on Toxicity and Outcomes in Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0757-5432","authenticated-orcid":false,"given":"Wan-Chuen","family":"Liao","sequence":"first","affiliation":[{"name":"Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PT, UK"},{"name":"School of Dentistry, College of Medicine, National Taiwan University, Taipei 10048, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-0558","authenticated-orcid":false,"given":"Hala","family":"Shokr","sequence":"additional","affiliation":[{"name":"Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK"},{"name":"The Christie NHS Foundation Trust, Manchester M20 4BX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Dempsey","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaye Janine","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6158-6645","authenticated-orcid":false,"given":"Li-Chia","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2147\/CMAR.S351744","article-title":"Technological advancements in external beam radiation therapy (EBRT): An indispensable tool for cancer treatment","volume":"14","author":"Koka","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.addr.2015.12.012","article-title":"Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements","volume":"109","author":"Her","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.7150\/jca.24665","article-title":"Angiotensin-converting enzyme inhibitors decrease the incidence of radiation-induced pneumonitis among lung cancer patients: A systematic review and meta-analysis","volume":"9","author":"Sun","year":"2018","journal-title":"J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eururo.2011.09.027","article-title":"Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature","volume":"61","author":"Bolla","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/cancers7020820","article-title":"Complications from stereotactic body radiotherapy for lung cancer","volume":"7","author":"Kang","year":"2015","journal-title":"Cancers"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2018.07.017","article-title":"Urologic complications following pelvic radiotherapy","volume":"122","author":"Lobo","year":"2018","journal-title":"Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00259-020-05074-5","article-title":"Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma","volume":"48","author":"Lee","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fowler, H., Belot, A., Ellis, L., Maringe, C., Luque-Fernandez, M.A., Njagi, E.N., Navani, N., Sarfati, D., and Rachet, B. (2020). Comorbidity prevalence among cancer patients: A population-based cohort study of four cancers. BMC Cancer, 20.","DOI":"10.1186\/s12885-019-6472-9"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.21873\/anticanres.11379","article-title":"Polypharmacy in older patients \u2265 70 years receiving palliative radiotherapy","volume":"37","author":"Nieder","year":"2017","journal-title":"Anticancer. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Diaconu, C.C., Cozma, M.A., Dobric\u0103, E.C., Gheorghe, G., Jichitu, A., Ionescu, V.A., Nicolae, A.C., Dr\u0103goi, C.M., and G\u0103man, M.A. (2021). Polypharmacy in the management of arterial hypertension-friend or foe?. Medicina, 57.","DOI":"10.3390\/medicina57121288"},{"key":"ref_12","first-page":"Cd009096","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"2014","author":"Li","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-18-0236","article-title":"Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events","volume":"24","author":"Pinter","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cllc.2015.08.007","article-title":"Renin-angiotensin system inhibitors might help to reduce the development of symptomatic radiation pneumonitis after stereotactic body radiotherapy for lung cancer","volume":"17","author":"Bracci","year":"2016","journal-title":"Clin. Lung Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Cong, C., Wang, Z., Liu, Y., Zhang, M., Zhou, H., Su, C., and Sun, M. (2023). Decreased risk of radiation pneumonitis with concurrent use of renin-angiotensin system inhibitors in thoracic radiation therapy of lung cancer. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1255786"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2015.09.013","article-title":"Can angiotensin-converting enzyme inhibitors reduce the incidence, severity, and duration of radiation proctitis?","volume":"94","author":"Alashkham","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.radonc.2022.01.014","article-title":"Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer","volume":"168","author":"Kerns","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1667\/0033-7587(2000)153[0405:CACEIP]2.0.CO;2","article-title":"Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis?","volume":"153","author":"Wang","year":"2000","journal-title":"Radiat. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ijrobp.2013.08.033","article-title":"Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database","volume":"87","author":"Wang","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e643","DOI":"10.1016\/j.prro.2015.07.003","article-title":"Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy","volume":"5","author":"Harder","year":"2015","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/COC.0000000000000324","article-title":"Decreased risk of radiation pneumonitis with coincident concurrent use of angiotensin-converting enzyme inhibitors in patients receiving lung stereotactic body radiation therapy","volume":"41","author":"Alite","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.ijrobp.2009.07.1743","article-title":"Renin-Angiotensin system suppression mitigates experimental radiation pneumonitis","volume":"75","author":"Ghosh","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijrobp.2010.05.017","article-title":"Computed tomography appearance of early radiation injury to the lung: Correlation with clinical and dosimetric factors","volume":"81","author":"Jenkins","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","article-title":"Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine","volume":"103","author":"Nakai","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zeman, M., Ska\u0142ba, W., Wilk, A.M., Cortez, A.J., Maciejewski, A., and Czarniecka, A. (2022). Impact of renin-angiotensin system inhibitors on the survival of patients with rectal cancer. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09919-0"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2022.2126250","article-title":"Angiotensin receptor blockade and stereotactic body radiation therapy for early stage lung cancer ARB & SBRT for early stage lung cancer","volume":"23","author":"Maloney","year":"2022","journal-title":"Cancer Biol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11060-018-2786-8","article-title":"Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?","volume":"138","author":"Happold","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"W-65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J. Chiropr. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1536867X1001000307","article-title":"METAAN: Stata module to perform fixed- or random-effects meta-analyses","volume":"10","author":"Kontopantelis","year":"2010","journal-title":"Stata J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijrobp.2011.11.013","article-title":"Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy","volume":"84","author":"Kharofa","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2018.10.035","article-title":"Daily lisinopril vs placebo for prevention of chemoradiation-induced pulmonary distress in patients with lung cancer (Alliance MC1221): A pilot double-blind randomized trial","volume":"103","author":"Sio","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/COC.0000000000000289","article-title":"Utility of the ACE inhibitor captopril in mitigating radiation-associated pulmonary toxicity in lung cancer: Results from NRG oncology RTOG 0123","volume":"41","author":"Small","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11060-017-2652-0","article-title":"Angiotensin receptor blockade: A novel approach for symptomatic radiation necrosis after stereotactic radiosurgery","volume":"136","author":"Chowdhary","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/ene.12746","article-title":"Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma","volume":"22","author":"Januel","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.12.034","article-title":"Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies","volume":"48","author":"Wedlake","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mumtaz, S., Rana, J.N., Choi, E.H., and Han, I. (2022). Microwave radiation and the brain: Mechanisms, current status, and future prospects. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169288"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"Hy1-4","DOI":"10.12659\/MSM.881698","article-title":"A possible prevention strategy of radiation pneumonitis: Combine radiotherapy with aerosol inhalation of hydrogen-rich solution","volume":"17","author":"Chuai","year":"2011","journal-title":"Med. Sci. Monit."},{"key":"ref_41","first-page":"9","article-title":"The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J. Manag. Care Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardiores.2004.04.030","article-title":"TGF-\u03b21 and angiotensin networking in cardiac remodeling","volume":"63","author":"Rosenkranz","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0360-3016(94)90187-2","article-title":"Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis","volume":"28","author":"Finkelstein","year":"1994","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ijrobp.2008.02.046","article-title":"Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury","volume":"71","author":"Anscher","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ijrobp.2010.03.058","article-title":"An improved model for predicting radiation pneumonitis incorporating clinical and dosimetric variables","volume":"80","author":"Jenkins","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.clgc.2016.03.009","article-title":"The incidence and risk of biochemical recurrence following radical radiotherapy for prostate cancer in men on angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)","volume":"14","author":"Alashkham","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1667\/RR2731.1","article-title":"Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment","volume":"178","author":"Lee","year":"2012","journal-title":"Radiat. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ijrobp.2008.09.058","article-title":"The AT1 receptor antagonist, L-158,809, prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment","volume":"73","author":"Robbins","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"E1073","DOI":"10.1503\/cmaj.101497","article-title":"Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: A meta-analysis of observational studies","volume":"183","author":"Yoon","year":"2011","journal-title":"Can. Med. Assoc. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S1470-2045(10)70271-0","article-title":"Blood-pressure drugs and cancer: Much ado about nothing?","volume":"12","author":"Lindholm","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_51","first-page":"884","article-title":"The role of the renin-angiotensin system inhibitors in malignancy: A review","volume":"11","author":"Yang","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.21873\/anticanres.13639","article-title":"Renin-angiotensin inhibition in combating malignancy: A review","volume":"39","author":"Rosenthal","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bulpitt, C.J., and Bulpitt, C.J. (1996). The advantages and disadvantages of randomised controlled trials. Randomised Controlled Clinical Trials, Springer.","DOI":"10.1007\/978-1-4615-6347-1"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/1\/105\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:29:32Z","timestamp":1759919372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/1\/105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ph18010105"],"URL":"https:\/\/doi.org\/10.3390\/ph18010105","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]}}}